Search
Compugen Ltd
CGENAdd to Watchlist
2.280USD
+0.150+7.04%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
213.26MMarket Cap
6.08P/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+7.04%
5 Days
+9.09%
1 Month
+2.70%
6 Months
+47.10%
Year to Date
+49.02%
1 Year
+29.55%
Key Figures
2.120Open
2.295High
495.00KVolume
6.08P/E TTM
LossP/E Dynamic
--Dividend TTM
0.53%Turnover Ratio
2.130Prev. Close
2.120Low
707.12KTurnover
LossP/E Static
4.24P/B
0.00%Div Yield TTM
26.03%ROA
3.23552wk High
2.77Volume Ratio
-14.23MNet Profit
93.54MShares
0.3750EPS TTM
2.77Beta
44.84%ROE
1.29552wk Low
8.22%Amplitude
16.18%Gross Margin
213.26MMarket Cap
-1.04Reward/Risk
3.90%Risk Rate
TradingKey Stock Score of Compugen Ltd
Currency: USD Updated: 2026-07-02Key Insights
Compugen Ltd's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 119 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 4.60.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Compugen Ltd's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Compugen Ltd Highlights
StrengthsRisks
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 117.47% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 72.76M.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Overvalued
The company’s latest PE is 6.08, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 13.75M shares, increasing 3.14% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 811.59K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.03.
Analyst Rating
Based on
5
analysts
Strong Buy
Current Rating
4.600
Target Price
+115.96%
Upside Space
Compugen Ltd News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Compugen Ltd Info
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.
Ticker SymbolCGEN
CompanyCompugen Ltd
CEOOphir (Eran)
Websitehttps://cgen.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Compugen Ltd (CGEN)?
The current price of Compugen Ltd (CGEN) is 2.28.
What is the symbol of Compugen Ltd?
The ticker symbol of Compugen Ltd is CGEN.
What is the 52-week high of Compugen Ltd?
The 52-week high of Compugen Ltd is 3.23.
What is the 52-week low of Compugen Ltd?
The 52-week low of Compugen Ltd is 1.29.
What is the market capitalization of Compugen Ltd?
The market capitalization of Compugen Ltd is 213.26M.
Is Compugen Ltd (CGEN) currently rated as Buy, Hold, or Sell?
According to analysts, Compugen Ltd (CGEN) has an overall rating of STRONG BUY, with a price target of 4.60.
What is the Earnings Per Share (EPS TTM) of Compugen Ltd (CGEN)?
The Earnings Per Share (EPS TTM) of Compugen Ltd (CGEN) is 0.38.